PepTracker App

Yesterday, HHS issued a draft interim policy that opened a safer, regulated path for peptides including BPC-157 and TB-500. This is a big step forward for access to innovation for more people, and over the last 2 years, we’ve been investing in the domestic infrastructure necessary for this exact moment. With Peptides+, clinician-led protocols built by the experts in the field plus a world-class infrastructure comes together in the one of the only companies that can deliver quality access to these newly eligible treatments. Through our US based facilities, we’ll be able to offer eligible customers access to the newly allowed peptides made 100% from start to finish in the US, with ongoing clinical support and an entirely US-based supply chain they can trust. Get an early look at what’s coming and sign up to be among the first in line to be in the know as we begin to roll this out: hims.com/peptides-plus Important disclaimers here: news.hims.com/disclaimers/ca…

BREAKING: HHS announces interim compounding access for six peptides. - BPC-157 - TB-500 - KPV - MOTS-c - Semax - Epitalon HHS says it won’t take enforcement action against qualifying pharmacies and physicians compounding these peptides under its conditions, including patient-specific prescriptions. A big step for prescription-based peptide access.

Your peptides may be coming fentanyl suppliers. Anhui Renchen Technology was indicted in 2023 for supplying the Sinaloa Cartel with fentanyl precursors. Their website currently sells semaglutide and melanotan II. Of roughly 200 Chinese firms TRM Labs tracked selling fentanyl precursors, at least 50 now sell peptides. The shipments enter the US in “master cartons” mislabelled as snack food, broken up by a domestic handler and mailed on. CBP has intercepted around 400 of those operations and seized over 130,000 vials in the past year. FDA records surfaced showing two deaths, one in July and one in September, reported after people injected untested black market retatrutide.

JUST IN: RFK Jr. pushes to create a regulated marketplace for peptides, declaring “Americans are going to be buying these anyway,” regardless of restrictions.

These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for retatrutide: > highest dose lost 28.3% of body weight in 80 wks > 70 lbs ave > 45% lost 30% or more of their body weight > 65% on the top dose no longer clinically obese Retatrutide is more dynamic than semaglutide and tirzepatide because it targets three receptors (GIP, GLP-1, and glucagon), versus one and two, respectively. Side effects, on the highest dose (12mg), were higher for retatrutide than tirzepatide (nausea and GI), with an 11.3% drop out rate. The lowest 4mg dose still delivered 19% loss with fewer dropouts than placebo.

Everyone’s on Ozempic